Novartis

Opens floodgates for more generic launches; 40 new brands expected

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

As part of the organisational overhaul unveiled in April, Novartis said that the cost cuts would be mainly from removing overlapping structures

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%

Novartis has licenced global rights to two Molecular Partners antiviral drugs that have potential to treat Covid-19 patients, the two companies said

ZURICH (Reuters) - Novartis joined rivals Merck, Johnson & Johnson and Roche in predicting the worst of the pandemic may be over for drugmakers, amid signs healthcare systems have learned how to cope with surging infections without shutting down all services.

Here are the top headlines of the day

It will also pay $51.25 million to resolve charges it funnelled money through three charitable foundations to cover co-payments of Medicare patients so they would purchase its drugs

A vaccine must be widely tested in humans before being administered to hundreds of millions, say experts

Core net income rises to $3.55 billion from $2.8 billion in 2019, against the average analyst forecast in a Refinitiv poll of $3.17 billion

Novartis is donating 130 million hydroxychloroquine doses to support efforts against the epidemic, though the European Union has so far said there is no proof it works.

Malaria, lupus and arthritis drug hydroxychloroquine is under clinical trials, says Novartis.

That is above the average of 404 drug price increases in the first three days of January over the past five years

BioAsia is an annual event in which stakeholders in the lifesciences sector discuss new innovations and explore possibility of business collaborations in the sector

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors

Basel-based Novartis sees cell and gene therapies eventually contributing about 15% of its revenue

Novartis shares were seen up 0.2%, premarket indicators showed.